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course of rheumatic diseases could reflect the abnormali-
ties in glycosylation/sialylation patterns of glycoproteins 
induced by acute-phase response.
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Introduction
There are evidences that the changes in the protein glyco-
sylation during the course of rheumatic diseases are impli-
cated in the pathogenesis of rheumatic diseases [1]. The 
association between changes in the glycosylation homeo-
stasis and pathogenic mechanism in rheumatic diseases is 
so constant and characteristic that it has been referred as 
“sugar printing the rheumatic diseases” [2]. More recent 
works indicate that not only the lack of galactose residues 
on immunoglobulin G itself but, rather, the concomitant 
absence of terminal sialic acid may be responsible for 
pro- and anti-inflammatory activity of IgG [3, 4]. It has 
been documented that the lack of galactose residues results 
in a concomitant lack of terminal sialic acid residues and 
increases the affinity for activating Fcγ receptors [5, 6]. 
Otherwise, the presence of glycan structure terminating in 
sialic acid residues reduces affinity of antibodies to cellular 
Fc receptors and enhances the anti-inflammatory activity 
exerted by G0 glycoforms of IgG [3, 4].
In the pathogenesis of rheumatic diseases are also impli-
cated the altered glycosylation of other than IgG plasma 
proteins such as fibronectin, transferrin, α1-acid glyco-
protein and haptoglobin [7–9]. Structurally, these are gly-
coproteins terminated with sialic acid residues, and their 
levels in the blood may be non-specific markers of the dis-
ease activity [10]. Therefore, the total level of sialic acid 
Abstract In the rheumatic diseases, the changes in 
the carbohydrate part of serum glycoproteins occur and 
these abnormalities can be monitored by serum level of 
total and free sialic acid. The aim of this study was to 
evaluate the total and free sialic acid level as a marker 
of inflammation activity (TSA) and the changes in gly-
cosylation of blood glycoproteins (FSA) in rheumatoid 
arthritis (RA), systemic sclerosis (SSc) and systemic 
lupus erythematosus (SLE). Studies were carried out 
in 50 patients with RA, 24 with SLE and 32 with SSc. 
TSA concentration was measured with an enzymatic, col-
orimetric method and FSA with a thiobarbituric method. 
The serum levels of TSA in RA and SLE patients were 
significantly increased compared to controls and in RA 
patients were higher than that in SSc patients. The mean 
serum level of FSA in RA patients was significantly 
higher, but in SSc patients significantly lower than that 
in the controls, and in RA patients was significantly 
higher than in SLE and in SSc patients. All acute-phase 
proteins were changed: Positive acute-phase proteins 
were elevated, and the negative protein was decreased. 
The positive acute-phase proteins positively correlated 
with the levels of TSA and FSA in RA and SSc patients. 
In SLE patients, TSA positively correlated with hap-
toglobin and α1-antitrypsin. In RA patients, there was 
the positive correlation of TSA and FSA with DAS 28. 
The changes in the serum levels of TSA and FSA in the 
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(TSA) can measure the activity of acute-phase reaction, but 
the free sialic acid (FSA) can measure the disturbances in 
sialylation of these glycoproteins during disease [11, 12]. 
The aim of this study was to evaluate the total and free 
sialic acid level as a marker of inflammation activity and 
the changes in glycosylation of serum glycoproteins in 
the course of rheumatoid arthritis (RA), systemic sclerosis 
(SSc) and systemic lupus erythematosus (SLE).
Methods
Patients
Studies were carried out in 50 patients with RA (40 
females and 10 males) aged from 25 to 85 years (mean age 
55 years), 24 with SLE (22 males and 2 females) aged from 
23 to 70 years (mean age 40 years) and 32 with SSc (27 
females and 5 males; 18 with diffuse cutaneous SSc and 
14 with limited cutaneous SSc) aged from 19 to 71 years 
(mean age 47 years) admitted to the Department of Rheu-
matology and Internal Diseases. The duration of the RA was 
from 2 months to 25 years, SLE from 1 to 21 years and SSc 
from 3 months to 15 years. The diagnosis of the disease was 
made on the basis of criteria given by American College of 
Rheumatology. RA patients were taking non-steroidal anti-
inflammatory and disease-modifying antirheumatic drugs 
such as methotrexate and sulfasalazine. The RA activity was 
evaluated by disease activity score (DAS 28) according to 
the following formula which included the number of tender 
(t28) and swollen (s28) joints, ESR and VAS:
To assess disease activity in SLE patients, the Physi-
cian’s global assessment (PGA) was used. It based on a 
DAS 28 = 0.56 × sqrt(t28) + 0.28 × sqrt(s28) + 0.7
× ln(ESR) + 0.014 × VAS
visual analog scale 0–100 mm, in which score “0” indicates 
an inactive disease (none of patients), score “1”—mild 
disease (3 patients), score “2”—moderate (13 patients) 
and score “3”—severe disease (8 patients). The 42 con-
trol subjects (33 women and 9 men) were recruited from 
mixed healthy hospital workers (mean age 42 years, range 
26–65). Blood samples were collected from each patient 
once on admission from a peripheral vein after a 12-h fast-
ing. Patients and controls gave informed consent and par-
ticipated in the study. The laboratory characteristics of the 
healthy subjects and patients are shown in the Table 1.
Laboratory analysis
ESR (normal range <10 mm/h for men and ≤20 mm/h for 
women up to 50 years, and ≤30 mm/h for women more 
than 50 years) was determined by Westergren method on 
the Sediplus S 2000 (Sarstedt, Germany). Hemoglobin 
level (normal range for women 12–16 g/dL and for men 
14–18 g/dL) and PLT (normal range 130–350 × 103/μL 
for adults) were determined by using routine methods on 
the hematological analyzer Advia 120 (Bayer, USA). The 
transferrin (TRF) concentration (normal range 2.0–3.6 g/L) 
was determined by the immunoturbidimetric method using 
Siemens test (Siemens Healthcare Diagnostics, Marburg, 
Germany) on BN II analyzer. CRP (CRP Vario test: nor-
mal range ≤5 mg/L), RF (Quantia RF test; lower than 
30 IU/mL are considered normal, and results between 30 
and 50 IU/mL as weakly positive), immunoglobulin G 
(Immunoglobulin G test; normal range 5.52–16.31 g/L for 
female; 5.40–18.22 for male), α1-antitrypsin (AAT) (Quan-
tia A1-Antitrypsin test; normal range 0.9–2.0 g/L), α1-acid 
glycoprotein (AGP) (Quantia A-1-AGP test; normal range 
0.5–1.2 g/L) and haptoglobin (Haptoglobin test; normal 
range 0.35–2.50 g/L for female; 0.14–2.58 g/L for male) 
were measured with an immunoturbidimetric methods 
Table 1  The results of laboratory tests in patients and controls
Data are medians and ranges. The differences between patients and controls estimated by Mann–Whitney U test. RA rheumatoid arthritis, SLE 
systemic lupus erythematosus, SSc systemic sclerosis, P < 0.05 significant difference, ESR erythrocyte sedimentation rate, Hb hemoglobin, PLT 
platelets count, RF rheumatoid factor, IgG immunoglobulin G, Anti-CCP autoantibodies to cyclic citrullinated peptide
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(Abbott, Wiesbaden, Germany) on the Architect c8000 ana-
lyzer (Abbott Laboratories, Abbott Park, USA). Autoanti-
bodies against cyclic citrullinated peptide (anti-CCP) were 
determined with a chemiluminescent microparticle immu-
noassay (CMIA) using the anti-CCP test (Abbott, Wies-
baden, Germany) on an Architect i2000 analyzer (Abbott 
Laboratories, Abbott Park, IL, USA). A cutoff of 5.0 U/mL 
was chosen, whereby a result of ≥5.0 was considered posi-
tive and a result of <5.0 was considered negative. 14 of RA, 
2 of SSc and 2 of SLE patients were RF positive (RF+).
TSA concentration was measured with a colorimetric, 
enzymatic method, using Enzy-Chrom Sialic Acid Assay 
Kit (BioAssay Systems, Hayward, CA, USA) on the Micro-
plate Fluorescence Reader FL600 (Bio-Tek, USA).
FSA was determined using the thiobarbituric method 
of Skoza and Mohos [13]. All reagents were from Sigma-
Aldrich Chemie GmbH. Measurements were performed at 
549 nm on the spectrophotometer Shimadzu UV-1202 (Shi-
madzu Europa GmbH, Duisburg, Germany).
Statistical analysis
The differences between the tested and control groups were 
evaluated by Mann–Whitney U test and the correlation 
between SA and acute-phase proteins by the calculation of 
Spearman’s rank correlation coefficient. The effect of the 
activity of rheumatic diseases on the TSA and FSA values 
was evaluated by the ANOVA rank Kruskal–Wallis test. 
Because the chance of finding one or more significant dif-
ferences in three tested groups was only 14.26 % (Bonfer-
roni correction), the post hoc multiple comparison analysis 
was performed. The GraphROC for Statistica version 10 
was used to evaluate the diagnostic sensitivity, specificity, 
positive (PPV) and negative predictive values (NPV), and 
the area under the receiver operating characteristic (ROC) 
curve.
Results
Table 1 presents the results of laboratory tests in the blood 
of patients and the comparison of them with the results of 
the controls. The mean values of ESR and RF were signifi-
cantly higher but Hb significantly lower, in patients with 
rheumatic diseases than that in the controls. The levels of 
PLT and anti-CCP were higher only in RA patients but IgG 
in SSc patients. The serum levels of acute-phase proteins 
are shown in Table 2. All acute-phase proteins in patients 
with rheumatic diseases were significantly changed in com-
parison with the controls: positive acute-phase proteins 
(CRP, AGP, HP and AAT) were elevated and the negative 
(TRF)—decreased. Total protein level was significantly 
diminished in RA and SLE patients.
The serum level of TSA in RA (mean ± SD; range 
2.47 ± 0.61; 1.69–5.28 mmol/L) and SLE patients 
(2.34 ± 0.31; 1.87–2.97 mmol/L) was significantly 
increased compared to controls (2.06 ± 0.21; 1.75–
2.54 mmol/L) (P < 0.001 for both) (Fig. 1). There was 
the significant difference in the serum TSA concentra-
tion between rheumatic diseases (H = 7.199; P = 0.027). 
The mean level of TSA in RA patients was higher than 
that in SSc patients (2.22 ± 0.45; 1.76–4.30 mmol/L) 
(P = 0.025).
The mean serum level of FSA in RA patients 
(mean ± SD; range 184.7 ± 43.8; 124.7–331.5 μmol/L) 
was significantly higher (P = 0.003) and in SSc patients 
(151.9 ± 40.0; 119.0–321.0 μmol/L) significantly lower 
(P = 0.018), than that in the controls (156.7 ± 20.9; 114.9–
195.9 μmol/L) (Fig. 2). There were significant differ-
ences in the serum FSA concentration between rheumatic 
diseases (H = 20.252; P < 0.001). The mean level in RA 
patients was significantly higher than that in SLE patients 
(155.9 ± 31.0; 115.8–225.5 μmol/L) (P = 0.012) and in 
SSc patients (P < 0.001).
Table 2  The results of acute-phase proteins in patients and controls
Data are medians and ranges. The differences between patients and controls estimated by Mann–Whitney U test. RA rheumatoid arthritis, SLE 
systemic lupus erythematosus, SSc systemic sclerosis, P < 0.05 significant difference, CRP C-reactive protein, AGP α1-acid glycoprotein, HP 
haptoglobin, AAT α1-antitrypsin, TRF transferrin, TP total protein
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There were positive correlation between positive acute-
phase proteins, CRP, AGP, HP, AAT and the levels of 
TSA and FSA, in RA and SSc patients (Table 3). In SLE 
patients, there was only the positive correlation HP and 
AAT with TSA. The negative acute-phase proteins, trans-
ferrin, correlated negatively with TSA and FSA only in 
RA patients. In RA patients, there was the positive cor-
relation of TSA and FSA with DAS 28 (R = 0.326 and 
R = 0.538, respectively). The further analysis revealed that 
for these relations were responsible mainly ESR and VAS. 
The higher relationship FSA than TSA with DAS 28 comes 
from the additional correlation of FSA with t28 and s28. 
RF does not correlate with TSA and FSA in any rheumatic 
diseases.
TSA and FSA levels did not differ according to disease 
activity in SLE patients evaluated by means of PGA scores 
(H = 3.926, P = 0.140 for TSA and H = 0.256, P = 0.879 
for FSA).
The sensitivity, specificity, PPV, NPV and the area under 
the ROC curve (AUC) of TSA and FSA in RA were lower 
than that of CRP and anti-CCP (Table 4). The diagnostic 
power (ACC) of TSA and FSA in RA was also lower than 
that of CRP and anti-CCP. The sensitivity, specificity, PPV 
and NPV of TSA in SLE were similar to that in RA. The 
diagnostic power of FSA in SSc was similar to that in RA.
Discussion
Existing data provide evidence that acute-phase proteins 
are involved in the inflammation and that effects are time-, 
concentration- and molecular conformation-dependent, 
especially are related with the status of glycosylation [14]. 
From the other hand, the alterations in the glycosylation of 
plasma proteins may be involved in the etiology of rheu-
matic diseases [1, 2]. There were a confirmed information 
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Fig. 1  TSA concentrations in patients with rheumatic diseases. C 
controls, RA rheumatoid arthritis, SSc systemic sclerosis, SLE sys-
temic lupus erythematosus
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Fig. 2  FSA concentrations in patients with rheumatic diseases. C 
controls, RA rheumatoid arthritis, SSc systemic sclerosis, SLE sys-
temic lupus erythematosus
Table 3  The correlation 
between acute-phase proteins 
and TSA and FSA
Data are Spearman rank 
correlation coefficients (R) 
and P values. RA rheumatoid 
arthritis, SLE systemic lupus 
erythematosus, SSc systemic 
sclerosis; P < 0.05 significant 
difference; CRP C-reactive 
protein, AGP α1-acid 
glycoprotein, HP haptoglobin, 
AAT α1-antitrypsin, TRF 
transferrin
TSA FSA
RA SLE SSc RA SLE SSc
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about the changes in the different forms of protein glyco-
sylation in rheumatic diseases. These involve galactosyla-
tion, fucosylation, mannosylation, sialylation and branch-
ing [8, 9, 15–17]. From this reason, human glycoproteins 
exist in many different glycoforms. The end position on 
N-glycans is often occupied by sialic acid and is known to 
be a biochemical marker for the diagnosis of glycosylation 
abnormalities in several pathological conditions, includ-
ing rheumatoid diseases. Therefore, we tested the concen-
tration of total sialic acid (TSA), as a non-specific marker 
of inflammation, and the concentration of free sialic acid 
(FSA), as a marker of sialylation disturbances in the sera of 
patients with RA, SLE and SSc.
We denote that the TSA and FSA levels in the sera of 
patients with RA were elevated in comparison with the 
controls. The results concerning TSA are in accordance 
with previously obtained by other authors [18, 19]. Addi-
tionally, the level of sialic acid could reflect the progres-
sion and the activity of rheumatoid arthritis as indicated in 
the analysis of correlation of TSA and FSA with the value 
of DAS 28. The analysis shows that in RA patients, TSA 
and FSA changed parallel with the alterations of RA activ-
ity measured by means of DAS 28. The detailed analysis 
indicated that mainly ESR and VAS are responsible for 
these correlations. Other authors suggested that a good cor-
relation between ESR and sialic acid could be a reason for 
use TSA in place of ESR as a marker of disease activity in 
RA patients [19]. Increased serum sialic acid has also been 
reported in inactive RA classified according to ACR crite-
ria for clinical remission of disease [12]. In our study, only 
two patients have the value of DAS 28 less than 2.6 that 
implies remission of disease. The other authors indicate on 
the association of relative sialylation of serum and synovial 
glycoproteins (e.g., fibronectin) with the progression and 
activity of rheumatoid arthritis [7]. In contrast to RA activ-
ity, the activity of SLE evaluated by PGA scores does not 
affect the serum levels of TSA and FSA.
This study demonstrates the association between the 
changes in TSA and FSA concentration and the levels 
of glycoproteins recommended as acute-phase proteins, 
especially in RA and SSc patients. The increased con-
centration of TSA in rheumatic diseases can concern the 
increased level of sialylated glycoproteins such as α1-acid 
glycoprotein, haptoglobin and α1-antitrypsin. These are 
called as positive proteins of acute-phase reaction and 
can be increased several-fold in response to inflammation, 
infection, and systemic tissue injury [20]. A good positive 
correlation between TSA and positive proteins of acute-
phase reaction reflects the linear association between the 
increase in TSA and disease activity. Additionally, the one 
non-glycosylated protein, CRP, also correlated with TSA 
and FSA, and this may suggest that both TSA and FSA can 
be treated as a non-specific markers of inflammation during 
rheumatic diseases (RA and SSc) [21, 22].
The most widely used indicators of the acute-phase 
response are the erythrocyte sedimentation rate and the 
plasma C-reactive protein concentration. ESR is an indirect 
measurement of plasma acute-phase protein concentrations 
and can be influenced by the size, shape, and the number 
of erythrocytes, as well as by other plasma constituents 
such as immunoglobulins. As has been shown in Table 1, 
in only SLE patients, IgG level was higher than that in the 
healthy persons but not differs from that in RA patients. 
From the other hand, systemic lupus erythematosus is 
one exception to the generalization that C-reactive protein 
concentrations correlate with the severity of inflammation 
[23]. Many patients with active systemic lupus erythema-
tosus do not have high plasma concentrations of CRP but 
do have marked increases during bacterial infection. There-
fore, CRP concentration in SLE patients might be lower 
than that in RA patients. The cause of low CRP concentra-
tions, incompatible with the inflammatory process, can be 
due to its binding to anti-CRP antibodies (mostly in class 
IgG) with the formation of immunological complexes [24]. 
It can be speculated that the low CRP concentration accom-
panying active inflammation in SLE patients should be the 
result the genetic polymorphism of single nucleotide in the 
promoter region of the C-reactive protein gene [25].
The elevated results of CRP in SSc patients in our study 
were observed in 34.4 % cases and elevated ESR results in 
43.7 % of subjects. Although, the mean CRP and ESR lev-
els were lower than that in RA patients, the frequency of 
elevation of these parameters in our study is higher than in 
the patients studied by the Canadian Scleroderma Research 
Group [26]. The occurrence of elevated CRP results in 
these studies was 25.7 % and elevated ESR results 38.2 %. 
Table 4  The diagnostic power 
of TSA and FSA in RA, SLE 
and SSc
ACC accuracy, PPV positive 
predictive value, NPV negative 
predictive value, AUC area 
under ROC curve, SE standard 
error
Test Sensitivity (%) Specificity (%) ACC (%) PPV (%) NPV (%) AUC (±SE)
CRP (RA) 84.8 100 90.5 100 80.0 0.965 ± 0.018
Anti-CCP (RA) 83.7 100 88.4 100 71.4 0.928 ± 0.031
TSA (RA) 66.0 85.3 74.1 86.1 64.4 0.748 ± 0.055
FSA (RA) 61.2 76.5 67.5 78.9 57.8 0.693 ± 0.057
TSA (SLE) 69.6 85.3 78.9 76.2 80.6 0.786 ± 0.063
FSA (SSc) 79.4 63.3 71.9 71.1 73.1 0.673 ± 0.071
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As was established in these large cohorts, an elevation of 
CRP level is more common in the diffuse cutaneous SSc 
subset, especially with early disease duration (≤3 years). 
More than half the patients suffered from diffuse cutaneous 
SSc (18 cases), and equally half the patients had disease 
lasting shorter than 3 years.
The diagnostic power of TSA and FSA resulting from 
ROC analysis indicates that these tests have lower sensi-
tivity, specificity, positive and negative predictive values, 
and the area under the ROC curves than that of CRP and 
anti-CCP in rheumatic disorders. CRP is generally consider 
as a marker of inflammation, but Maury et al. [18] inves-
tigated that CRP elevation during SLE was not accompa-
nied by recognized intercurrent infection or other super-
imposed cause of tissue injury and inflammation in 61 % 
of instances. In those studies, CRP was increased (above 
5 mg/L) in 33 % of patients. In our study, there was 42 % 
(10 cases) of SLE patients with the value of CRP higher 
than 5 mg/L, than majority of them (7 cases) suffered from 
renal insufficiency with proteinuria.
From the other hand, the changes in free sialic acid lev-
els can be consider as a result of disturbances in glycosyla-
tion of sialylated proteins. Therefore, its correlation with 
sialylated glycoproteins and additionally with CRP can 
suggest the FSA reflects the abnormalities in glycosyla-
tion of protein caused by activity of inflammation during 
rheumatic diseases. The negative protein of acute-phase 
reaction, transferrin, also correlated with TSA and FSA 
concentration, but there was a negative correlation. This 
phenomenon was observed only in RA patients. The gly-
coprotein sensitive to alteration in glycosylation is α1-
acid glycoprotein, because contains 42 % carbohydrate in 
weight, and the glycan component is made by five heter-
opolysaccharides N-linked to the protein chain [27]. The 
oligosaccharide moiety expressed on the surface of AGP is 
extensively heterogeneous in sialylation, fucosylation and 
branching degree [28]. Therefore, the several glycoforms 
can be detected in healthy human plasma [29]. Altered gly-
cosylation patterns in plasma AGP and haptoglobin have 
been found to be associated with the pathogenesis of rheu-
matoid arthritis [9]. RA patients showed the significant var-
iations in the mannosylation patterns in AGP and HP.
It should be not generalized that the alterations of pro-
teins glycosylation in rheumatic diseases are quite uni-
form. For example, glycosylation abnormalities of IgG in 
rheumatic diseases are different [2]. Testing the relation-
ship between exposed galactose and N-acetylglucosamine 
on IgG from RA, juvenile chronic arthritis (JCA) and SSc 
patients, the different changes were found. In patients with 
RA and JCA, the galactose and N-acetylglucosamine are 
inversely related but in SSc patients, galactose expression 
on IgG decreased while N-acetylglucosamine remained 
similar to normal level. The oligosaccharide profile of IgG 
glycans (proportion of digalactosyl-fucosylated to agalac-
tosyl-fucosylated structures) from RA patients was also 
significantly different from JCA and SLE patients. In our 
study, the level of FSA in SSc patients was decreased in 
contrast to RA patients where FSA level was increased. 
Also, the TSA level in RA patients was different from SLE 
and SSc patients. These changes suggest that the unique 
pattern of glycosylation is associated with different rheu-
matological changes.
Transferrin, the negative protein of acute-phase response, 
also alters the glycosylation pattern in rheumatoid arthritis 
[8]. Although, the concentration of total transferrin dimin-
ishes in RA, SLA and SSc patients, the changes in glyco-
sylation can contribute to increased level of sialic acid. In 
RA patients was observed the significant shift toward the 
highly branched and sialylated glycan chains of transfer-
rin. These results indicate that the changes in synthetic rate 
of transferrin as the effect of acute-phase response and the 
changes in glycosylation are regulated independently.
In conclusion, the changes in the serum TSA and 
FSA could reflect the acute-phase response (increase 
of positive acute-phase proteins) and the alterations in 
glycosylation/sialylation patterns of glycoproteins induced 
by acute-phase response. The changes in TSA and FSA lev-
els can also reflect the disease activity in RA and SSc.
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